Chemotherapy in advanced pancreatic cancer

International Journal of Pancreatology

Volumn 21, Issue 1, 1997, Pages 39-41

  Dippold, Wolfgang ^a   Bernhard, Helga ^a   Meyer Zum Büschenfelde, Karl Hermann ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

5 fluorouracil; biomodulation; chemotherapy; folinic acid; interferon 2A; Pancreatic cancer

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL; FOLINIC ACID;

ADENOCARCINOMA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030980563     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreas cancer. Semin Oncol 1994; 21:58-66.
2. Moore M. Multicenter Study Group improvements in survival and clinical benefit with the use of gemcitabine (GEM) as first-line therapy for advanced pancreatic cancer: a randomized trial. Proc ASCO 1995; 547.
3. Bukowski RM, Balcerzak SP, O'Brian RM, Bonnett JD, Chen TT. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A South-West Oncology Group study. Cancer 1983; 52: 1577-1582.
4. Oster MW, Gray R, Panasci L, et al. Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin and mitomycin (FSM). Cancer 1986; 57: 29-33.
5. Gastrointestinal Tumor Study Group. Phase II studies of drug combination in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycin-C plus fluorouracil. J Clin Oncol 1986; 1794-1798.
6. Grem JL, Chu E, Boarman D, Balis FM, Murphy RF, McAtee N, Allegra CJ. Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations. Semin Oncol 1992; 19, 36-44.
7. Van der Wilt CL, Pinedo HM, Smid K, Cloos J, Noordhuis P, Peters GJ. Effect of folinic acid on fluorouracil activity and expression of thymidilate synthase. Semin Oncol 1992; 19: 16-24.
8. Bernhard H, Jäger-Arand E, Bernhard G, Heike M, Klein O, Riemann JF, Meyer zum Büschenfelde K-H, Dippold W, Knuth A. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase 11 trial. Br J Cancer 1995; 71: 102-105.
9. Crown J, Casper ES, Botet J, Murray P, Kelsen DP. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9: 1682-1686.
10. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B. Phase II evaluation of fluorouracil and recombinant a-2a interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992; 70: 2073-2076.
11. Scheithauer W, Pfeffel F, Kornek G, Marczell A, Wiltschke C, Funovics J. A phase 11 trial of 5-fluorouracil, leucovorin and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 1992; 70: 1864-1866.
12. Johnston GP, Lenz H-J, Leichmann GC, Danenberg DK, Allegra JC, Dannenberg VP, Leichmann L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-1412.